Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Michael B. Atkins, Opeyemi Jegede, David F. McDermott, Naomi B. Haas, Mehmet Asim Bilen, Mark N. Stein, Jeffrey A. Sosman, Elizabeth R. Plimack, Robert S. Alter, Moshe Chaim Ornstein, Michael E. Hurwitz, David J. Peace, David Johnson Einstein, Paul J. Catalano, Hans J. Hammers, Meredith M. Regan
Institutions: Georgetown Lombardi Comprehensive Cancer Center, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Abramson Cancer Center, University of Pennsylvania, Winship Cancer Institute, Columbia University Irving Medical Center, Northwestern University, Northwestern Medicine, Fox Chase Cancer Center, Hackensack University Medical Center, Cleveland Clinic, Yale University, University of Illinois Chicago, The University of Texas Southwestern Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W4324136625